IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
出版年份 2016 全文链接
标题
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume 108, Issue 12, Pages djw182
出版商
Oxford University Press (OUP)
发表日期
2016-08-31
DOI
10.1093/jnci/djw182
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma
- (2015) S.-E. Lamhamedi-Cherradi et al. MOLECULAR CANCER THERAPEUTICS
- Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma
- (2015) Marco Santoro et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1
- (2015) Eleni M. Tomazou et al. Cell Reports
- Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications
- (2015) Yunyun Jiang et al. Oncotarget
- EWS-FLI1 Utilizes Divergent Chromatin Remodeling Mechanisms to Directly Activate or Repress Enhancer Elements in Ewing Sarcoma
- (2014) Nicolò Riggi et al. CANCER CELL
- MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas
- (2014) H. Zhong et al. MOLECULAR CANCER THERAPEUTICS
- Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group
- (2014) Lars M. Wagner et al. PEDIATRIC BLOOD & CANCER
- Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway
- (2013) Dong Hoon Shin et al. JNCI-Journal of the National Cancer Institute
- Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
- (2013) Gary K Schwartz et al. LANCET ONCOLOGY
- Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma
- (2013) Z Kang et al. ONCOGENE
- Modeling Ewing sarcoma tumors in vitro with 3D scaffolds
- (2013) E. L. S. Fong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting the EWSR1-FLI1 Oncogene-Induced Protein Kinase PKC- Abolishes Ewing Sarcoma Growth
- (2012) D. Surdez et al. CANCER RESEARCH
- Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors
- (2012) A. Naing et al. CLINICAL CANCER RESEARCH
- Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's Sarcoma
- (2012) Cecilia Garofalo et al. MOLECULAR ENDOCRINOLOGY
- Dual IGF-I/II-Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth
- (2011) J. Gao et al. CANCER RESEARCH
- Expression of insulin-like growth factor system components in Ewing’s sarcoma and their association with survival
- (2011) Katia Scotlandi et al. EUROPEAN JOURNAL OF CANCER
- R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study
- (2011) Alberto S. Pappo et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing's and Osteogenic Sarcoma Models
- (2011) P. J. Beltran et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling
- (2011) C Garofalo et al. ONCOGENE
- Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program
- (2011) E. Anders Kolb et al. PEDIATRIC BLOOD & CANCER
- Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures
- (2011) Vivek Subbiah et al. PLoS One
- Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy
- (2010) Xuerong Wang et al. CANCER BIOLOGY & THERAPY
- A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors
- (2010) R. Kurzrock et al. CLINICAL CANCER RESEARCH
- Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies
- (2010) D. Olmos et al. MOLECULAR CANCER THERAPEUTICS
- Mnk earmarks eIF4E for cancer therapy
- (2010) N. Hay PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma
- (2009) R. T. Kurmasheva et al. CANCER RESEARCH
- Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1
- (2009) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting insulin-like growth factor type 1 receptor in cancer therapy
- (2009) Francesco Atzori et al. Targeted Oncology
- Development of IGF-IR inhibitors in pediatric sarcomas
- (2009) E. Anders Kolb et al. Current Oncology Reports
- Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program
- (2008) E. Anders Kolb et al. PEDIATRIC BLOOD & CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now